[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100499926":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":35,"responsibleParty":178,"collaborators":24,"id":180,"slug":181,"hasResults":182,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":24,"eligibilityCriteria":186,"healthyVolunteers":182,"sex":187,"minAge":188,"maxAge":24,"enrollmentInfo":189,"targetDuration":24,"studyType":192,"phases":193,"briefSummary":195,"conditions":196,"keywords":24,"overallStatus":38,"whyStopped":24,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":207},{"fullName":5,"class":6},"Betta Pharmaceuticals Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation","EXPERIMENTAL","Oral tablets taken in escalating levels to determine MTD\u002FRP2D. Each treatment cycle will be 21 days in duration with BPI-460372 administered, once daily (QD).",[13],"Drug: BPI-460372",{"label":15,"type":10,"description":16,"interventionNames":17},"Dose Expansion","Oral tablets administered at MTD\u002FRP2D defined dose. Each treatment cycle will be 21 days in duration with BPI-460372 administered, once daily (QD)",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","BPI-460372","Subjects will receive BPI-460372 until disease progression",[9,15],null,[26,31],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Mengzhao Wang, Ph.D","CONTACT","010-69155039","mengzhaowang@sina.com",{"name":32,"role":28,"phone":33,"phoneExt":24,"email":34},"Xiaohong Han, Ph.D","010-69156114","hanxiaohong@pumch.cn",[36,55,64,77,90,103,116,129,144,153,166],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Peking Union Medical College Hospital","RECRUITING","Beijing","Beijing Municipality","100032","China","CN",{"type":45,"coordinates":46},"Point",[47,48],116.39723,39.9075,{"lat":48,"lon":47},[51,53],{"name":52,"role":28,"phone":29,"phoneExt":24,"email":30},"Mengzhao Wang",{"name":54,"role":28,"phone":33,"phoneExt":24,"email":34},"Xiaohong Han",{"facility":56,"status":57,"city":39,"state":40,"zip":24,"country":42,"countryCode":43,"cosmosGeoPoint":58,"geoPoint":60,"contacts":61},"Cancer Hospital Chinese Academy of Medical Sciences","NOT_YET_RECRUITING",{"type":45,"coordinates":59},[47,48],{"lat":48,"lon":47},[62],{"name":63,"role":28,"phone":24,"phoneExt":24,"email":24},"Yutao Liu",{"facility":65,"status":38,"city":66,"state":67,"zip":68,"country":42,"countryCode":43,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Affiliated Hospital of Hebei University","Baoding","Hebei","050031",{"type":45,"coordinates":70},[71,72],115.46246,38.87288,{"lat":72,"lon":71},[75],{"name":76,"role":28,"phone":24,"phoneExt":24,"email":24},"Aimin Zang",{"facility":78,"status":57,"city":79,"state":80,"zip":81,"country":42,"countryCode":43,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Harbin Medical University Cancer Hospital","Harbin","Heilongjiang","150081",{"type":45,"coordinates":83},[84,85],126.65,45.75,{"lat":85,"lon":84},[88],{"name":89,"role":28,"phone":24,"phoneExt":24,"email":24},"Yan Yu",{"facility":91,"status":57,"city":92,"state":93,"zip":94,"country":42,"countryCode":43,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Tongji Hospital Tongji Medical College of HUST","Wuhan","Hubei","430030",{"type":45,"coordinates":96},[97,98],114.26667,30.58333,{"lat":98,"lon":97},[101],{"name":102,"role":28,"phone":24,"phoneExt":24,"email":24},"Qian Chu",{"facility":104,"status":38,"city":105,"state":106,"zip":107,"country":42,"countryCode":43,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"Hunan Cancer Hospital","Changsha","Hunan","410031",{"type":45,"coordinates":109},[110,111],112.97087,28.19874,{"lat":111,"lon":110},[114],{"name":115,"role":28,"phone":24,"phoneExt":24,"email":24},"Lin Wu",{"facility":117,"status":57,"city":118,"state":119,"zip":120,"country":42,"countryCode":43,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"China-Japan Union Hospital of Jilin University","Changchun","Jilin","130033",{"type":45,"coordinates":122},[123,124],125.32278,43.88,{"lat":124,"lon":123},[127],{"name":128,"role":28,"phone":24,"phoneExt":24,"email":24},"Linlin Liu",{"facility":130,"status":38,"city":131,"state":132,"zip":133,"country":42,"countryCode":43,"cosmosGeoPoint":134,"geoPoint":138,"contacts":139},"Central Hospital Affiliated to Shandong First Medical University","Jinan","Shandong","250013",{"type":45,"coordinates":135},[136,137],116.99722,36.66833,{"lat":137,"lon":136},[140,142],{"name":141,"role":28,"phone":24,"phoneExt":24,"email":24},"Meili Sun",{"name":143,"role":28,"phone":24,"phoneExt":24,"email":24},"Qing Wen",{"facility":145,"status":57,"city":131,"state":132,"zip":146,"country":42,"countryCode":43,"cosmosGeoPoint":147,"geoPoint":149,"contacts":150},"Shandong Cancer Hospital","250117",{"type":45,"coordinates":148},[136,137],{"lat":137,"lon":136},[151],{"name":152,"role":28,"phone":24,"phoneExt":24,"email":24},"Ligang Xing",{"facility":154,"status":57,"city":155,"state":156,"zip":157,"country":42,"countryCode":43,"cosmosGeoPoint":158,"geoPoint":162,"contacts":163},"Taizhou Hospital of Zhejiang Province","Taizhou","Zhejiang","317000",{"type":45,"coordinates":159},[160,161],121.43312,28.66266,{"lat":161,"lon":160},[164],{"name":165,"role":28,"phone":24,"phoneExt":24,"email":24},"Dongqing Lv",{"facility":167,"status":57,"city":168,"state":168,"zip":169,"country":42,"countryCode":43,"cosmosGeoPoint":170,"geoPoint":174,"contacts":175},"The First Affiliated Hospital of Zhengzhou University","Zhengzhou","450052",{"type":45,"coordinates":171},[172,173],113.64861,34.75778,{"lat":173,"lon":172},[176],{"name":177,"role":28,"phone":24,"phoneExt":24,"email":24},"Xingya Li",{"type":179,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100499926","phase-1-a-study-of-bpi-460372-in-advanced-solid-tumor-patients-100499926",false,"NCT05789602","A Study of BPI-460372 in Advanced Solid Tumor Patients","A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-460372 in Advanced Solid Tumor Patients","Inclusion Criteria:\n\n* Signed informed consent;\n* Age ≥18, male and female patients；\n* Expected survival ≥ 3 months；\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1;\n* Dose escalation phase: histologically or cytologically confirmed locally advanced or metastatic solid tumor patients, who had disease progression after standard therapy, intolerable to standard therapy, refuse to standard therapy or for whom no standard therapy exists;\n* Dose expansion phase: histologically or cytologically confirmed locally advanced Malignant mesothelioma, Epithelioid hemangioendothelioma or other diagnosed solid tumor patients with NF2 defects, YAP\u002FTAZ fusion, LATS1\u002F2 mutations, and other Hippo signaling pathway abnormalities , who had disease progression after standard therapy, intolerable to standard therapy, refuse to standard therapy or for whom no standard therapy exists;\n* Evaluable lesion required for dose escalation phase and at least 1 measurable lesion as per RECIST v1.1 or mRECIST v1.1 required for dose expansion phase;\n\nExclusion Criteria:\n\n* Patients who have previously received a TEAD inhibitor;\n* Inadequate wash-out of prior therapies described per protocol, which may include anti-tumor therapies, tumor adjuvant drugs, organ or stem cell transplantation，etc；\n* Patients with severe or unstable systemic disease, unstable\u002Fsymptomatic CNS metastasis, meningeal metastasis and spinal cord compression，malignant tumors, cardiac disease, bleeding or embolic disease, infectious disease, conditions affecting drug swallow and absorption, medical history leading to chronic diarrhea, etc;\n* Pregnancy or lactation;\n* Other conditions considered not appropriate to participate in this trial by the investigators.","ALL","18 Years",{"count":190,"type":191},82,"ESTIMATED","INTERVENTIONAL",[194],"PHASE1","This study is an open-label, single arm, dose escalation and dose expansion phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BPI-460372 in solid tumor patients.",[197],"Advanced Solid Tumor","2025-01-22",{"date":200,"type":201},"2025-01-27","ACTUAL",{"date":203,"type":201},"2023-04-24",{"date":205,"type":191},"2026-04-17",{"name":5,"class":6},11]